Compare HLIT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIT | TRVI |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1996 | 2019 |
| Metric | HLIT | TRVI |
|---|---|---|
| Price | $12.51 | $14.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $14.67 | ★ $21.55 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.73 | N/A |
| Revenue Next Year | $18.36 | N/A |
| P/E Ratio | $190.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $5.38 |
| 52 Week High | $15.39 | $16.12 |
| Indicator | HLIT | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 51.15 |
| Support Level | $9.92 | $10.07 |
| Resistance Level | N/A | $16.12 |
| Average True Range (ATR) | 0.76 | 0.80 |
| MACD | 0.11 | -0.05 |
| Stochastic Oscillator | 45.30 | 40.11 |
Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.